SG/CALL/ABBOTT LABORATORIES/100/0.1/20.09.24 Stock

Warrant

DE000SQ3G8X8

Delayed Deutsche Boerse AG 06:06:16 2024-06-20 am EDT
0.69 EUR +6.15% Intraday chart for SG/CALL/ABBOTT LABORATORIES/100/0.1/20.09.24
Current month+12.07%
1 month-14.47%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-06-20 0.69 +6.15%
24-06-19 0.65 -7.14%
24-06-18 0.7 +2.94%
24-06-17 0.68 -1.45%
24-06-14 0.69 0.00%

Delayed Quote Deutsche Boerse AG

Last update June 20, 2024 at 06:06 am EDT

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying ABBOTT LABORATORIES
IssuerLogo Issuer Société Générale Société Générale
WKN SQ3G8X
ISINDE000SQ3G8X8
Date issued 2022-10-27
Strike 100 $
Maturity 2024-09-20 (93 Days)
Parity 10 : 1
Emission price 1.87
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 2.55
Lowest since issue 0.49
Spread 0.06
Spread %8.00%

Company Profile

Abbott Laboratories specializes in the research, development, manufacturing and marketing of pharmaceutical and medical products. Net sales break down by family of products as follows: - diagnostic systems and instruments (39.1%); - vascular devices (24.7%): endoprosthetic systems, dilation catheters, arterial closures, etc.; - nutrition products (12.1%): pediatric nutrition products, nutritional supplements, and dietetic products; - medicine (8.2%): anesthetics, antiviral products, antibiotics, inhibitors, anti-inflammatories, etc.; - other (15.9%). Net sales are distributed geographically as follows: the United States (38.5%), Germany (5.8%), China (5.6%), India (4.4%), Switzerland (4.1%), Japan (3.8%), Netherlands (2.7%) and others (35.1%).
Sector
-
More about the company

Ratings for Abbott Laboratories

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Abbott Laboratories

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
104 USD
Average target price
125.4 USD
Spread / Average Target
+20.56%
Consensus